Clinical trial
A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC-205, Fused to Full-length Tumor Antigen NY-ESO-1) in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
NCT02661100 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC-205, Fused to Full-length Tumor Antigen NY-ESO-1) in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
- Lead sponsor
- Case Comprehensive Cancer Center
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- January 31, 2017
- Completion date
- July 31, 2018
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
advanced triple negative breast cancer, malignant melanoma, mesothelioma, non small cell lung cancer, small cell lung cancer, urothelial cancer